This is an early-stage preclinical announcement with no near-term catalyst for revenue or clinical data. Monitor for future IND filings or partnership developments, but no immediate trading action is warranted.
Price Chart
Executive Summary
Galmed Pharmaceuticals announced preclinical results from a collaboration with Tissue Dynamics, identifying a previously unknown metabolic pathway for cardiac fibrosis and demonstrating that a combination of Aramchol Meglumine and a selective PPARα agonist reduced fibrotic burden by approximately 4-fold (p<0.001) in human cardiac organoid models. A new patent application has been filed and IND-enabling activities are being prepared. This is an early-stage preclinical finding with no clinical data or regulatory milestones yet.
Key Facts
- Preclinical study in human cardiac organoids showed combination of Aramchol Meglumine and PPARα agonist reduced fibrotic burden by ~4-fold (p<0.001)
- A new patent application has been filed based on these findings
- Preparations are underway to support future IND-enabling activities
- Galmed is a clinical-stage biopharmaceutical company with a $5M market cap
- No financial terms, revenue, or clinical trial data were disclosed in this filing
Financial Impact
No financial impact disclosed; preclinical research stage with no revenue or clinical milestones
Risk Factors
- Preclinical results may not translate to human clinical outcomes
- No clinical trial data or regulatory milestones yet
- Company has a very small market cap ($5M) and limited financial resources
- Forward-looking statements subject to significant risks and uncertainties
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-026756 |
| Document: form6-k.htm | 0001493152-26-026756 |
| Document: 0001493152-26-026756-index-headers.html | 0001493152-26-026756 |
| Document: 0001493152-26-026756-index.html | 0001493152-26-026756 |
| Document: 0001493152-26-026756.txt | 0001493152-26-026756 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | 6-K | $4.63 $3.63 | ▼ −21.71% | ▼ −21.37% | — |
Sep 4, 2026 7w ago | EFFECT | $3.88 $4.63 | ▼ −19.33% | ▼ −20.54% | — |
Sep 3, 2026 7w ago | 6-K | $3.88 $4.63 | ▲ +19.33% | ▲ +20.54% | — |
Sep 2, 2026 7w ago | 6-K | $3.92 $4.63 | ▲ +18.11% | ▲ +19.26% | — |
Aug 19, 2026 9w ago | 6-K | $4.77 $4.33 | ▼ −9.22% | ▼ −8.84% | — |
Aug 17, 2026 10w ago | 6-K | $0.5134 | awaiting T+5 | — | — |
Jul 28, 2026 12w ago | 6-K | $0.5340 $0.5754 | ▲ +7.75% | ▲ +3.64% | — |
Jul 16, 2026 14w ago | 6-K | $0.5501 $0.5530 | ▲ +0.53% | ▲ +2.20% | — |
Jun 22, 2026 18w ago | 6-K | $0.5641 $0.5709 | ▲ +1.21% | ▲ +1.66% | — |
Jun 8, 2026 20w ago | 6-K | $0.4693 $0.6160 | ▲ +31.26% | ▲ +29.15% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers